Key facts
- KA-EX’s last known valuation is $15.0M (Jan 2025).
- It has raised $31.6M; the latest was Equity Crowdfunding ($6.1M) in Apr 2026.
- Notable investors include Artemon, German Media Pool, ProSiebenSat.1 Licensing, mediaforgrowth.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for KA-EX
- ·The full record, as it builds
Funding rounds
No funding rounds for KA-EX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KA-EX
Developer of a clinically tested cortisol stress reduction supplement designed for athletes and high-performers seeking faster recovery, better sleep and sustained daily energy. The company offers a citrus-flavored recovery product formulated with phosphatidylserine, amino acids, electrolytes, antioxidants, and functional carbohydrates that help replenish muscle glycogen, support muscle repair, restore acid-base balance, and improve sleep quality, enabling competitive and recreational athletes, sports teams, and other high-performers to reduce stress-related performance plateaus, enhance mood, boost immune resilience, and maximize training progress.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Zurich, Switzerland
- Founded
- 2016
- Employees
- 27
- Website
- ka-ex.com/
- Ownership
- Privately Held (backing)
KA-EX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KA-EX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KA-EX in its N-PORT filings yet. We sweep new filings monthly.